Please login to the form below

Not currently logged in
Email:
Password:

K-V resumes limited manufacturing

K-V Pharmaceutical has received permission from the US Food and Drug Administration to resume production of its potassium chloride products

K-V Pharmaceutical Company, which has encountered regulatory and legal difficulties over the past few years, has received permission from the US Food and Drug Administration (FDA) to resume production of its potassium chloride products following a successful inspection of the company's manufacturing facilities.

K-V recalled all of the products it manufactures early last year after FDA inspections turned up manufacturing problems including oversized tablets that could result in overdoses. The company also halted manufacturing and shipping of further products at that time.

The speciality pharma firm's consent decree with the FDA makes resumption of manufacturing and shipment of the products contingent on successful inspections.

The results of an inspection conducted in mid-August have allowed the company to begin producing the potassium chloride products Micro-K 10mEq and Micro-K 8mEq, which are indicated for the prevention and treatment of hypokalaemia, a condition characterised by low serum potassium that can lead to cardiovascular complications and impaired muscle function.

K-V said it intends to begin shipping the potassium chloride products next week, and that the FDA is expected to conduct additional inspections to decide whether other products may also be returned to the marketplace in the near future.

K-V markets its products through Ther-Rx Corporation, its branded drug subsidiary. Its portfolio includes the estrogen therapy Evamist (estradiol transdermal spray), which is intended to treat hot flashes, and the anti-infectives Clindesse and Gynazole-1, which treat bacterial vaginosis and yeast infections.

The company's generic drug subsidiary Ethex ceased operations earlier this year after pleading guilty to criminal charges brought by the US Department of Justice over its failure to notify authorities about potentially dangerous manufacturing problems.

10th September 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics